Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q3 FY22 results · Oct–Dec 2021
Glenmark Pharmaceuticals reported revenue from operations of ₹3,173.41 crore (up 13.9% from Q3 FY21) and net profit of ₹239.75 crore (down 3.4% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,173.41 | 2,786.76 | +13.9% | 3,147.45 | +0.8% |
| Other income | 13.89 | 15.09 | −7.9% | (13.07) | Turned profit |
| Total income | 3,187.31 | 2,801.85 | +13.8% | 3,134.38 | +1.7% |
| Profit before tax | 343.04 | 347.97 | −1.4% | 384.96 | −10.9% |
| Net profit for the period | 239.75 | 248.18 | −3.4% | 274.81 | −12.8% |
| EPS, basic (₹) | 7.86 | 8.80 | −10.7% | 9.74 | −19.3% |
| Net margin (%) | 7.6 | 8.9 | 8.7 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,033.05 | 1,972.48 | +3.1% | 2,180.87 | −6.8% |
| Other income | 216.74 | 81.13 | +167.2% | 80.70 | +168.6% |
| Total income | 2,249.80 | 2,053.61 | +9.6% | 2,261.56 | −0.5% |
| Profit before tax | 636.65 | 533.01 | +19.4% | 877.61 | −27.5% |
| Net profit for the period | 548.52 | 442.32 | +24.0% | 754.26 | −27.3% |
| EPS, basic (₹) | 19.44 | 15.68 | +24.0% | 26.73 | −27.3% |
| Net margin (%) | 27.0 | 22.4 | 34.6 |
Consolidated
- Filed with BSE
- 12 Feb 2022, 18:44 IST
- Board meeting
- 11 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Feb 2022, 18:44 IST
- Board meeting
- 11 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE